In close collaboration with Jens Juul Holst, we conducted a series of infusion studies on the satiety effects of other gut hormones including GLP-2 and PYY
Because Tirzepatide activates an additional hormonal pathway, many obesity specialists believe it may provide stronger appetite suppression and metabolic benefits compared to Semaglutide alone
Demand is likely to rise as obesity treatment and cardiovascular risk reduction widen the eligible patient pool
Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjr MS, Krarup N, Lawitz E, Ratziu V, Sanyal AJ, Schattenberg JM, Newsome PN
The FDA has also approved two GLP-1 diabetes drugs, Bydureon BCISE and Trulicity, for patients 10 y age and older